Bowel diseases Etrasimod Etrolizumab IND Filgotinib IND Mirikizumab Risankizumab Skyrizi is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. IND Indicated for UC (collitis ulcerosa) with demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies. IND Teduglutide IND Upadacitinib Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. IND Extension of indication to include treatment of moderately to severely active Crohn's disease in adult patients. IND Vedolizumab IND Other chronic immune diseases Avapritinib Advanced systemic mastocytosis (AdvSM). AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. IND Non-advanced systemic mastocytosis IND Baricitinib Systemic lupus erythematosus IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. IND Berotralstat Budesonide modified released capsule Canakinumab IND Coacillium topical Dupilumab IND FCR 001 Leniolisib Marnetegragene autotemcel Mavorixafor Ritlecitinib Sizavaleucel Sutimlimab Voclosporin Vonoprazan Rheumatism Anifrolumab Baricitinib IND Bimekizumab Extension of indication to include Bimzelx, alone or in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more DMARDs. IND Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis) IND Cyclobenzaprine hydrochloride Sarilumab IND Secukinumab IND Tocilizumab BS Upadacitinib IND Skin diseases Baricitinib IND Beremagene geperpavec Berkenschorsextract Concentrate of proteolytic enzymes enriched in bromelain IND Dabocemagene autoficel Deucravacitinib Difelikefalin Dupilumab Dupixent is geïndiceerd bij kinderen van 6 maanden tot 6 jaar met ernstige atopische dermatitis die in aanmerking komen voor systemische behandeling. IND Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. IND Lebrikizumab Regenerative Skin Tissue Roflumilast topicaal Ruxolitinib phosphate Secukinumab IND Sirolimus G Spesolimab Tralokinumab IND Unknown Olopatadine / mometasone